ReviewOncology letters2018
The role of chemokine receptor 9/chemokine ligand 25 signaling: From immune cells to cancer cells.
Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Inflammatory proteins in pre-diagnosis versus at-diagnosis samples associated with differentiated thyroid cancer.International journal of cancer · 2026Observational
- Osteoarthritis Bone Marrow MSCs Retain Regenerative Competence and Chemokine Responsiveness for Drug-Based In Situ Tissue Engineering.Stem cells international · 2025Article
- Downregulation of chemokine receptor 9 facilitates CD4Nature communications · 2023Article
- Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer.Seminars in cancer biology · 2022Review
- Chemokine Receptor Antagonists: Role in Oncology.Current oncology reports · 2021Review
- CCL25 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Article
- Dietary Derived Micronutrients Modulate Immune Responses Through Innate Lymphoid Cells.Frontiers in immunology · 2021Review
- Article
- Thymus‑expressed chemokine secreted by breast cancer cells promotes metastasis and inhibits apoptosis.Oncology reports · 2020Article
- CCR9 Promotes Migration and Invasion of Lung Adenocarcinoma Cancer Stem Cells.International journal of medical sciences · 2020Article
- Discovery of crucial cytokines associated with abdominal aortic aneurysm formation by protein array analysis.Experimental biology and medicine (Maywood, N.J.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokine ligand 25 (CCL25) and chemokine receptor 9 (CCR9) are important regulators of migration, proliferation and apoptosis in leukocytes and cancer cells. Blocking of the CCR9/CCL25 signal has been demonstrated to be a potential novel cancer therapy. Research into CCR9 and CCL25 has revealed their associated upstream and downstream signaling pathways; CCR9 is regulated by several immunological factors, including NOTCH, interleukin 2, interleukin 4 and retinoic acid. NOTCH in particular, has been revealed to be a crucial upstream regulator of CCR9. Furthermore, proteins including matrix metalloproteinases, P-glycoprotein, Ezrin/Radixin/Moesin and Livin are regulated via phosphatidylinositol-3 kinase/protein kinase B, which are in turn stimulated by CCR9/CCL25. This is a review of the current literature on the functions and signaling pathways of CCR9/CCL25.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.